Carcinoma Transitional Cell/*mortality/pathology/surgery Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Risk Assessment/methods Urinary Bladder/*pathology/surgery Urinary Bladder Neoplasms/*mortality/pathology/surgery Urothelium/*pathology/surgery histology meta-analysis urinary bladder neoplasms

Carcinoma Transitional Cell/epidemiology/*pathology Disease Progression Humans Neoplasm Invasiveness Neoplasm Recurrence Local/epidemiology Neoplasm Staging Prognosis Urinary Bladder Neoplasms/epidemiology/*pathology Bladder cancer Progression Staging Substage T1 Urothelial carcinoma pT1

Radical cystectomy Vi-rads muscle-invasive bladder cancer urothelial carcinoma

Antineoplastic Agents/*therapeutic use Chemotherapy Adjuvant/*statistics & numerical data *Cystectomy Global Health Guideline Adherence/statistics & numerical data Humans Models Statistical Neoadjuvant Therapy/*statistics & numerical data Neoplasm Invasiveness Practice Guidelines as Topic Practice Patterns Physicians'/*statistics & numerical data Urinary Bladder Neoplasms/*drug therapy/pathology/surgery

Biomarkers Tumor/*urine DNA Neoplasm/*urine Humans RNA Neoplasm/*urine Urinary Bladder Neoplasms/*genetics/*urine Watchful Waiting Biomarkers Bladder Genetic Surveillance

Cystectomy/adverse effects/*methods Humans Laser Therapy/adverse effects/*methods Neoplasm Invasiveness Treatment Outcome Urethra Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Laser surgery Systematic review and meta-analysis Transurethral resection

Vi-rads bladder cancer bladder cancer staging inter-reader agreement multiparametric magnetic resonance imaging muscle-invasive bladder cancer

Antihypertensive Agents/*adverse effects/therapeutic use Disease Susceptibility Dose-Response Relationship Drug Humans Hypertension/complications/drug therapy/etiology Kidney Neoplasms/*epidemiology/*etiology Odds Ratio Publication Bias Risk Assessment Risk Factors Urinary Bladder Neoplasms/*epidemiology/*etiology antihypertensive medications bladder cancer kidney cancer meta-analysis risk interest.

5-ala 5-aminolaevulinic acid Hal Pdd accuracy meta-analysis bladder cancer blue light cystoscopy cystoscopy hexaminolevulinate narrow band imaging photodynamic diagnosis fluorescence consultant for Janssen Ferring Photocure Taris Spectrum Pacific Edge QED Abbvie Johnson & Johnson Seattle Genetics Nucleix Aduro and BMS. Ashish Kamat is is a consultant for Photocure. Mihir Desai is a consultant for Procept Biorobotics and Auris Surgical. Yair Lotan is a consultant for Photocure. Angela Smith is an investigator for Urogen and a consultant for FerGene Urogen and Merck.

Cystectomy/*methods Humans Neoplasm Invasiveness Urethra Urinary Bladder Neoplasms/pathology/*surgery Bladder tumor En bloc resection Meta-analysis Transurethral resection

Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Smoking/*adverse effects Survival Rate Treatment Outcome Urinary Bladder Neoplasms/drug therapy/*mortality/*surgery cigarette smoking cystectomy recurrence survival urinary bladder neoplasms

Adjuvants Immunologic Cystectomy Humans *Kidney Transplantation/adverse effects Risk Factors *Urinary Bladder Neoplasms/epidemiology Bcg Bladder cancer Cáncer vesical Kidney transplantation Trasplante renal

Biomarkers Tumor/genetics Carcinoma/genetics Gene Expression/genetics Gene Expression Profiling/methods Gene Expression Regulation Neoplastic/genetics Humans Neoplasm Recurrence Local/genetics Odds Ratio Prognosis RNA Circular/*genetics Survival Analysis Transcriptome/genetics Urinary Bladder/pathology Urinary Bladder Neoplasms/*genetics/metabolism bladder cancer circular RNA meta-analysis

Blood Loss Surgical/statistics & numerical data Cystectomy/*methods Humans Length of Stay/statistics & numerical data Lymph Node Excision *Minimally Invasive Surgical Procedures Operative Time Postoperative Complications/epidemiology Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*surgery Bladder cancer Meta-analysis Minimally invasive Open radical cystectomy Randomized controlled trials

Cystectomy/*methods Female Humans Male Observational Studies as Topic Robotic Surgical Procedures/*methods Urinary Bladder Neoplasms/surgery Urinary Diversion/*methods

Case-Control Studies Humans *Polymorphism Single Nucleotide Promoter Regions Genetic Urinary Bladder Neoplasms/*genetics Vascular Endothelial Growth Factor A/*genetics Bladder cancer Meta-analysis Polymorphism Vascular endothelial growth factor competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Cystectomy/*methods Humans Laparoscopy/*methods Minimally Invasive Surgical Procedures/methods Robotic Surgical Procedures/*methods Treatment Outcome Urinary Bladder Neoplasms/*surgery Urologic Surgical Procedures/*methods

5 alpha reductase inhibitors androgen deprivation therapy androgen receptor bladder cancer

Carcinoma Transitional Cell/pathology/*radiotherapy/*surgery *Cystectomy Humans Neoplasm Invasiveness *Radiotherapy Adjuvant Urinary Bladder Neoplasms/pathology/*radiotherapy/*surgery Cystectomie Cystectomy Local recurrence Muscle-invasive bladder cancer Prognosis Pronostic Radiotherapy Radiothérapie Récidive locale Tumeur de vessie infiltrant le muscle

Cystectomy/*adverse effects Female Humans Postoperative Complications/*etiology Urinary Bladder Neoplasms/*surgery Vaginal Diseases/*etiology